Regarding TCGA patients, TMPRSS2-ERG fusion was detected in 28.6% (140/489) of localized primary prostate cancer out of which 60% (84/140) exhibited both PCP4 deletion and TMPRSS2-ERG fusion. This evidence concerns the gene PCP4 and Familial prostate cancer.